Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;120(1):7-20.
doi: 10.1111/add.16646. Epub 2024 Sep 25.

Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review

Caroline Gregory  1 , Krishan Yadav  1   2 , Jordyn Linders  3 , Lindsey Sikora  4 , Debra Eagles  1   2
Affiliations

Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review

Caroline Gregory et al. Addiction. 2025 Jan.

Abstract

Background and aims: Buprenorphine is an evidence-based treatment for opioid use disorder, and the risk of precipitated withdrawal contributes to its underuse. The goal of this systematic review was to determine the incidence of buprenorphine-precipitated withdrawal in adults with opioid use disorder.

Methods: This systematic review was registered on PROSPERO (CRD42023437634). We searched Medline, Embase Classic + Embase, and Cochrane CENTRAL from inception to 10 November 2023, and included original research that reported the incidence of sublingual buprenorphine-precipitated withdrawal in adults with opioid use disorder. Primary screening was completed by four independent reviewers. Full text review, data extraction and risk of bias assessments using the Newcastle Ottawa Scale and the Cochrane Risk of Bias 2 tool were completed by two independent reviewers. The primary outcome was precipitated withdrawal. Secondary outcomes were baseline opioids used, induction dose, initial Clinical Opiate Withdrawal Scale (COWS) score, location of induction, definition and severity of precipitated withdrawal and adverse events. The range of incidence of precipitated withdrawal across studies was described.

Results: Our search yielded 10 197 unique citations. Twenty-one cohort and five randomized trials met inclusion criteria (n = 4497, range 20-1293). The overall incidence of precipitated withdrawal ranged from 0 to 13.2%. Nine studies defined precipitated withdrawal; definitions were inconsistent. Most patients used heroin at baseline. The most common initial dose of buprenorphine was between 2 mg and 8 mg (range: 0.075 mg-24 mg). Initial minimum COWS score ranged from 5 to 13. Induction locations included home, inpatient, emergency department, pre-hospital, outpatient and residential units. Of the fifteen studies with cases of precipitated withdrawal, nine studies did not report the severity of withdrawal experienced. Other induction-related adverse events varied. The overall quality of included studies was poor.

Conclusions: The best available evidence suggests the incidence of buprenorphine-precipitated withdrawal in adults with opioid use disorder is low and should not be a barrier to use.

Keywords: buprenorphine; buprenorphine‐naloxone; opioid addiction; opioid use disorder; opioid‐agonist therapy; precipitated withdrawal.

PubMed Disclaimer

References

REFERENCES

    1. Products ‐ Vital Statistics Rapid Release ‐ Provisional Drug Overdose Data [Internet]. 2023 [cited 2023 Jun 16]. Available from: https://www-cdc-gov.myaccess.library.utoronto.ca/nchs/nvss/vsrr/drug-ove...
    1. Abuse NI on D. Drug Overdose Death Rates|National Institute on Drug Abuse (NIDA) [Internet]. 2024 [cited 2024 Jun 13]. Available from: https://nida.nih.gov/research‐topics/trends‐statistics/overdose‐death‐rates
    1. Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017;2017(2):CD002025. https://doi.org/10.1002/14651858.CD002025.pub5
    1. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137–145. https://doi.org/10.7326/M17-3107
    1. Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, et al. CIHR Canadian Research Initiative in Substance Misuse Management of opioid use disorders: a national clinical practice guideline. CMAJ Can Med Assoc J. 2018;190(9):E247–E257. https://doi.org/10.1503/cmaj.170958

Publication types

MeSH terms

Grants and funding

LinkOut - more resources